{
  "id": 10773230,
  "title": "Dyadic at Lytham Partners: push from platform to sales",
  "url": "https://urgent.news/2026/09/29/dyadic-at-lytham-partners-push-from-platform-to-sales",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-29T20:25:11.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/dyadic-at-lytham-partners-push-from-platform-to-sales-93CH-4923497"
  },
  "original_language": "en",
  "account": null,
  "summary": "Dyadic Applied BioSolutions announced a shift from platform development to commercial execution at the Lytham Partners Fall 2026 Investor Conference. The company now has products in market and multiple revenue streams, including direct product sales, licensing fees, milestone payments, and profit-sharing arrangements. Dyadic's commercial push is supported by an industrial fungal gene expression platform developed over 30 years, which is being applied across life sciences, food nutrition, and bioindustrial uses. The company is focusing on high-value biopharma proteins, lower-cost food and industrial proteins, and aims to reduce contamination risks and improve batch-to-batch consistency.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "BuildDirect at Lytham Partners Fall 2026 Investor Conference: buy-and-build push",
        "url": "https://urgent.news/2026/09/29/builddirect-at-lytham-partners-fall-2026-investor-conference-buy-and",
        "published": "2026-09-29T21:39:22.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}